e-learning
resources
Virtual 2020
Pre-Congress Content
Real-world data and registries of thoracic oncology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Non small cell lung cancer: options and outcome of treatment beyond second line
T. Erdélyi (Budapest, Hungary), A. Bíró (Budapest, Hungary), Z. Matics (Budapest, Hungary), L. Koch (Budapest, Hungary), L. Tamási (Budapest, Hungary), V. Müller (Budapest, Hungary)
Source:
Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Session:
Real-world data and registries of thoracic oncology
Session type:
E-poster session
Number:
1691
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Erdélyi (Budapest, Hungary), A. Bíró (Budapest, Hungary), Z. Matics (Budapest, Hungary), L. Koch (Budapest, Hungary), L. Tamási (Budapest, Hungary), V. Müller (Budapest, Hungary). Non small cell lung cancer: options and outcome of treatment beyond second line. 1691
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Radiotherapy in small cell lung cancer: patient options
Source: Virtual Congress 2020 – Thoracic oncology
Year: 2020
Treatment of extensive-stage small cell lung carcinoma: current status and future prospects
Source: Eur Respir J 2010; 35: 202-215
Year: 2010
Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation
Source: Annual Congress 2011 - Quality management for lung cancer patients
Year: 2011
Endoscopical laser treatment in combined therapy non small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 463s
Year: 2002
Small cell lung cancer patients and their responses to treatment
Source: Eur Respir J 2004; 24: Suppl. 48, 301s
Year: 2004
Lung cancer: does age affect treatment strategy?
Source: Eur Respir Mon; 2009: 43:306–326
Year: 2009
Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 400s
Year: 2002
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer (ED SCLC)
Source: International Congress 2019 – Treatment of lung cancer
Year: 2019
Surgical treatment of small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 172s
Year: 2005
Check point inhibitors in peri-operative non small cell lung cancer strategy
Source: ERS Research Seminar 2017 – Immunotherapy: a new standard of care in thoracic malignancies?
Year: 2017
Survival of patients with relapsing small cell lung cancer (SCLC) after new line chemotherapy administration
Source: Eur Respir J 2005; 26: Suppl. 49, 78s
Year: 2005
European treatment guidelines: small cell lung cancer (SCLC)
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
Gefitinib in the non small cell lung cancer treatment: contribution to prolongation and quality of survival
Source: Eur Respir J 2004; 24: Suppl. 48, 303s
Year: 2004
Giant non small cell lung cancer – diagnosis and treatment
Source: Annual Congress 2008 - Congenital lung lesions and emphysema; lung cancer surgery
Year: 2008
New treatment options for nonsmall cell lung cancer and small cell lung cancer
Source: Annual Congress 2006 - PG12 - Small cell lung cancer management
Year: 2006
Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008
Systemic therapy. non small cell lung cancer stage I and II: treatment standards and new development
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
Rates of treatment response and median survival in advanced non small cell lung cancer patients
Source: Eur Respir J 2004; 24: Suppl. 48, 302s
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept